Nature Study Links Liver Steatosis to 44.2% CRC Metastasis Survival via MYC Pathway
Updated
Updated · Nature.com · Jul 1
Nature Study Links Liver Steatosis to 44.2% CRC Metastasis Survival via MYC Pathway
1 articles · Updated · Nature.com · Jul 1
Summary
Patients with colorectal cancer and liver steatosis were found to develop more aggressive “replacement” liver metastases, a subtype tied to less than 44.2% five-year overall survival versus 73.4% for encapsulated lesions.
The study traced that shift to steatosis-driven fatty acid oxidation, which stabilizes MYC through acetylation; MYC then boosts proline synthesis and collagen production, helping replacement metastases grow.
Targeting MYC, P5CS or COL1A1 suppressed the occurrence and growth of replacement metastases in patient-derived organoids, mouse models and patient-derived xenografts.
Spatial metabolite and protein analyses from patient samples supported the mechanism, showing higher proline, collagen and related signaling in replacement metastases, especially in steatotic livers.
The findings identify a potential treatment strategy for replacement liver metastases, for which no approved targeted therapies currently exist.
Recent research published between 2025 and 2026 has revealed that fatty liver disease creates a unique metabolic environment that actively fuels the progression of metastatic colorectal cancer (CRC). This environment causes cancer cells to undergo metabolic reprogramming, helping them adapt, thrive, and meet their increased energy demands as they spread to new organs. As a result, CRC metastasis becomes more aggressive. Understanding this critical link highlights the importance of considering liver health in cancer care and opens new possibilities for targeted therapies and improved patient outcomes.